Variable inactivation of human factor VIII from different sources by human factor VIII inhibitors.
The source of human factor VIIII (FVIII) had a marked effect on the inhibitory activity of a panel of eight human FVIII inhibitors. Use of conventional FVIII concentrates gave lower inhibitor titres whereas a monoclonal antibody purified FVIII concentrate gave titres similar to or greater than those with plasma. Addition of phospholipid (PL) protected highly purified FVIII against inhibition. The content of PL-bound FVIII in concentrates may account for the observed differences.
Littlewood
J D
JD
Department of Clinical Veterinary Medicine, University of Cambridge.
Bevan
S A
SA
Kemball-Cook
G
G
Evans
R J
RJ
Barrowcliffe
T W
TW
D000818:Animals; D001323:Autoantibodies / Q000096:biosynthesis / Q000502:physiology*; D004285:Dogs; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D010743:Phospholipids / Q000378:metabolism / Q000494:pharmacology; D015203:Reproducibility of Results; D014841:von Willebrand Factor / Q000502:physiology
D001323:Autoantibodies; D010743:Phospholipids; D014841:von Willebrand Factor; D005169:Factor VIII